Top Page
Biofrontera
(NASDAQ:BFRI)
Biofrontera (BFRI) vs. SPDR S&P 500 ETF (SPY)
Biofrontera Business Overview & Revenue Model
Biofrontera Earnings Call Summary
Biofrontera Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 39.18M | 37.30M | 34.07M | 28.67M | 24.10M | 18.85M |
| Gross Profit | 24.16M | 18.70M | 16.63M | 13.49M | 11.36M | 9.78M |
| EBITDA | -15.41M | -14.44M | -18.45M | 934.00K | -36.76M | -7.49M |
| Net Income | -16.59M | -17.76M | -20.13M | -640.00K | -37.71M | -10.99M |
Balance Sheet | ||||||
| Total Assets | 20.14M | 22.10M | 27.93M | 50.88M | 53.22M | 24.14M |
| Cash, Cash Equivalents and Short-Term Investments | 7.24M | 5.91M | 1.42M | 27.76M | 24.55M | 8.08M |
| Total Debt | 5.00M | 4.92M | 5.40M | 1.35M | 0.00 | 0.00 |
| Total Liabilities | 24.81M | 17.67M | 23.14M | 27.00M | 41.88M | 18.31M |
| Stockholders Equity | -4.67M | 4.43M | 4.79M | 23.88M | 11.34M | 5.83M |
Cash Flow | ||||||
| Free Cash Flow | -9.34M | -10.28M | -24.90M | -16.24M | -26.73M | -12.37M |
| Operating Cash Flow | -9.39M | -10.27M | -24.89M | -16.20M | -26.71M | -12.37M |
| Investing Cash Flow | -5.00K | -3.00K | 619.00K | -5.16M | -11.00K | 0.00 |
| Financing Cash Flow | 12.25M | 14.84M | 8.41M | 14.02M | 43.19M | 13.19M |
Biofrontera Technical Analysis
Biofrontera Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
65 Neutral | $13.88M | ― | 3.29% | ― | -26.17% | ― | |
51 Neutral | $7.95B | -0.40 | -41.62% | 2.21% | 22.29% | -1.85% | |
50 Neutral | $9.01M | ― | -531.54% | ― | 11.20% | 63.16% | |
46 Neutral | $5.46M | ― | -52.05% | ― | -29.64% | 73.63% | |
| ― | $227.41M | ― | -58.27% | ― | ― | ― | |
46 Neutral | $19.61M | ― | -52.69% | ― | ― | ― | |
44 Neutral | $6.17M | ― | -25.65% | ― | 19.22% | 98.73% |
Biofrontera Corporate Events
On August 11, 2025, Biofrontera Inc. announced the appointment of George Jones as Chief Commercial Officer, effective August 25, 2025. Jones, with over 25 years of experience in the pharmaceutical and biotech sectors, will oversee the company’s commercial functions. This appointment comes as Biofrontera strengthens its management following the acquisition of all rights and assets related to Ameluz® and RhodoLED® for the U.S. market from Biofrontera AG. The acquisition is expected to bring the company closer to cash break-even by reducing royalty payments. Jones’ extensive experience in commercial leadership is anticipated to accelerate Biofrontera’s growth and enhance its market access strategies.
On June 30, 2025, Biofrontera Inc. finalized an agreement with Biofrontera AG to acquire all U.S. rights to Ameluz® and RhodoLED®. This strategic transaction involves a royalty payment structure and grants Biofrontera AG a 10% equity stake in Biofrontera Inc. through Series D Convertible Preferred Stock. Additionally, a private placement of Series C Preferred Stock was initiated on June 27, 2025, to fund the acquisition, with proceeds expected to reach $11 million. This move is expected to enhance Biofrontera Inc.’s market presence in the U.S. and streamline its operations by consolidating rights to its key products.
On June 30, 2025, Biofrontera Inc. announced a significant restructuring of its relationship with Biofrontera AG, acquiring all U.S. rights to Ameluz® and RhodoLED® backed by an $11 million investment led by existing investors. This agreement reduces the royalty rate on Ameluz® sales, aiming to drive the company towards profitability and strengthen its presence in the U.S. dermatology market. The restructuring allows Biofrontera Inc. to assume full control over manufacturing, regulatory, and commercial responsibilities in the U.S., aligning long-term interests with Biofrontera AG through a 10% equity stake. The move is expected to enhance operational agility and support the company’s growth strategy, including an upcoming FDA submission for treating superficial basal cell carcinoma.
On June 12, 2025, Biofrontera Inc. held its Annual Meeting of Stockholders, where key decisions were made to shape the company’s future. Stockholders elected Heikki Lanckriet as a Class I director, approved an increase in authorized common stock shares, agreed to adjourn the meeting if necessary for further proxy solicitation, and ratified the appointment of CBIZ CPAs P.C. as the independent accounting firm for the fiscal year ending December 31, 2025. These decisions are expected to enhance Biofrontera’s operational capabilities and strategic positioning in the biotechnology sector.
On June 11, 2025, Biofrontera Inc. announced that it is in negotiations with Biofrontera AG regarding potential changes to their cooperation, including a possible combination of the two companies or adjustments to their license and supply agreement. These negotiations could lead to the transfer of certain rights and obligations from Biofrontera AG to Biofrontera Inc., as well as a reduction in the transfer price for Biofrontera Inc.’s licensed products sold in the U.S. The terms of any agreement are yet to be finalized and are subject to numerous conditions.
On June 3, 2025, Biofrontera Inc. filed a supplement to its Proxy Statement to update stockholders on voting procedures for their 2025 Annual Meeting. The supplement clarifies that Proposals 2 and 3 are considered routine matters under NYSE rules, allowing brokers to vote on them without instructions from shareholders, contrary to previous disclosures. Stockholders are urged to review these changes and vote accordingly.